A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days
Latest Information Update: 07 May 2020
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Pearl Therapeutics
- 21 Mar 2020 Results of pooled analysis of four studies (NCT01980615, NCT02189304, NCT03075267, NCT02197975) presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 27 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Oct 2014 Status changed from recruiting to active, no longer recruiting, according to the ClinicalTrials.gov record.